Sionna Therapeutics On a Mission to Revolutionize the Cystic Fibrosis Treatment Paradigm March 2nd 2026 Disclaimers and forward-looking statements This presentation contains forward-looking statements of Sionna Therapeutics, Inc. ("Sionna", "the Company", "we", "us", or "our") that involve substantial risks and uncertainties. All statements other than historical factual information are forward-looking statements, including without limitation statements regarding our goal of transforming the treatment paradi ...

United Bankshares, Inc. (UBSI) Investor Presentation March 2, 2026 FORWARD LOOKING STATEMENTS This presentation and statements made by United Bankshares, Inc. ("UBSI") and its management contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are intended to be covered by the safe harbor provisions for forward-looking statements contained in the Private Securities Litigation Re ...

Kilroy Realty Corporation Investor Presentation March 2026 Kilroy Oyster Point Phase 2 | South San Francisco, CA Where Innovation Works Company Overview Where Innovation Works 2 Who is Kilroy? San Francisco 27% Other Bay Area 17% Los Angeles 20% San Diego 19% Seattle 14% Austin 3% Technology Life Science 51% & Health Care 19% Professional, Business, and Other Services 9% F.I.R.E. 7% Media 6% Other 8% ABR (1) % by Industry Stabilized Occupancy (%) / Leased (%) 81.6% / 83.8% Signed But Not Commenced Space 220 ...

2 Delivering on the promise of Prime Editing Corporate Presentation March 2026 1 Forward Looking Statements This presentation contains forward-looking statements of Prime Medicine, Inc. ("Prime", "we" or "our") within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. These forward-looking statements contain information about our current and future prospects and our operations, which are based on currently available information. All statements other than statements of historica ...

Cautionary Statements March 2, 2026 March Investor Presentation Non-GAAP Financial Measures & Cautionary Statements Non-GAAP Financial Measures This presentation of Ventas, Inc. (the "Company," "we," "us," "our" and similar terms) includes certain financial performance measures not defined by generally accepted accounting principles in the United States ("GAAP"), such as such as Nareit FFO, Normalized FFO, Net Operating Income ("NOI"), Same- Store Cash NOI, Same-Store Cash NOI Margin, Same-Store Cash NOI Gr ...

Global. Connected. Sustainable. INVESTOR PRESENTATION March 2026 The meeting place for companies, technologies and data Digital Realty Overview 2 A Global Data Center and Connectivity Platform Supporting our Customers' Critical IT Architecture 5,500+ Customers (1) 232,500 Cross Connects (1) 55+ Metros (1) 300+ Data Centers EQUITY & ENTERPRISE VALUE TOP PUBLICLY TRADED U.S. REIT INVESTMENT GRADE RATINGS (5) BBB Baa2 BBB+ LARGEST PUBLICLY TRADED U.S. REIT (4) 2016 ADDED TO THE S&P 500 INDEX $54 Bn $73 Bn EQUI ...

Robinhood Markets, Inc. Robinhood Investor Presentation Disclaimers Investor Presentation March 2, 2026 About Robinhood Robinhood Markets, Inc. (NASDAQ: HOOD) transformed financial services by introducing commission-free stock trading and democratizing access to the markets for millions of investors. Today, Robinhood, through its subsidiaries, lets you trade stocks, options, futures, swaps (which include event contracts), and crypto, invest for retirement, earn with Robinhood Gold, and access an expert-mana ...

Investor Presentation M a r c h 2 0 2 6 • All amounts in millions of US Dollars unless otherwise noted. • This presentation makes reference to certain non-GAAP measures, including local currency ("LC") revenue growth rate, internal revenue growth rate, Adjusted EBITDA ("AEBITDA"), Adjusted EBITDA from recurring revenue percentage, Adjusted EPS ("AEPS"), free cash flow, assets under management ("AUM") and fee-paying assets under management ("FPAUM"). Please refer to Appendix for reconciliations to the most d ...

NASDAQ COMMON: XOMA NASDAQ PERPETUAL PREFERRED SHARES: XOMAP, XOMAO THE ROYALTY AGGREGATOR FOR BIOTECH COMPANIES Q1 2026 CORPORATE PRESENTATION XOMA ROYALTY – WHAT WE DO Royalties Milestones Science Structuring DISCLAIMERS Certain statements in this presentation are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including statements regarding: future potential monetization opportunities, active transactions w ...

ZUSDURI (formerly UGN-102) Approved by FDA! ZUSDURI is the first and only FDA-approved medication for recurrent low-grade intermediate-risk non-muscle invasive bladder cancer Transforming Urothelial Cancer Care Through Innovation March 2026 Disclaimers This investor presentation contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995, including, without limitation: the estimated addressable patient population and market and revenue opportunity for ...